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EXECUTIVE SUMMARY
The biotechnology industry in Maine consists of
approximately 80 businesses. These companies are
engaged in research and development and the manu-
facturing and provision of a wide variety of products
and services. The businesses cover a broad spec-
trum of the biotechnology industry, from human
diagnostics to marine biotechnology to genomics
and proteomics. Biotechnology firms are highly con-
centrated in southern Maine, but they also operate
in ten of the states sixteen counties. A study of the
industry conducted in 2002 found that these firms
generated a combined $432 million in annual sales
and employed 3,690 workers. Including multiplier
effects, the biotechnology industry contributed $685
million in output to the Maine economy in 2002 and
supported 7,135 Maine jobs.
This report presents the findings from a survey
of biotechnology firms located in Maine. The pur-
pose of the survey, conducted during the spring of
2003, was to collect information on a variety of
issues related to the companies operations and the
states business climate for biotechnology. Some of
the issues addressed in the survey include the
research and development activities of Maine bio-
technology companies, partnerships formed within
the biotechnology industry, and the companies par-
ticipation in government-sponsored business assis-
tance programs. The survey results present a snap
shot of the industry in 2002, which can be used to
establish a baseline against which to gauge future
growth and changes to the industry in Maine.
The survey results suggest that Maine biotech-
nology companies are actively involved in research
and development. Large companies generally fi-
nance the majority of their research and develop-
ment expenditures through their own revenue
sources, while small businesses are likely to receive
support for research and development from state-
sponsored programs such as those administered by
the Maine Technology Institute. These research
and development activities appear to result in new
innovations, as 78% of the businesses plan to re-
lease a new product within the next three years.
Further, Maine biotechnology companies hold an
average of 2.3 patents and 0.7 patents pending.
Opportunities for interaction among Maine bio-
technology businesses and other organizations in
Maine seem to be restricted by the diversity of
businesses within the industry, and the limited
awareness of the science and technology resources
available across the state. In almost every respect,
the biotechnology businesses in Maine are more
likely to engage in cooperative activities with part-
ners from outside of the state than from within.
Thirty-five percent of Maine biotechnology busi-
nesses plan to form a joint venture in the near future
with an out-of-state partner, compared to 22% that
plan to do so with another Maine firm. By a ratio of
nearly five to one, businesses plan to obtain technol-
ogy from a university outside of Maine rather than
from an in-state institution.
Biotechnology companies generally believe that
many of the costs of doing business in the state are
harmful to their growth. The majority of firms
report that the costs health care are, workers com-
pensation, utilities, and state and local taxes are
relevant to the growth of their business. Further,
statistical analysis of the survey results suggests
that these cost factors have a significant negative
effect on a biotechnology companys ability to grow
in Maine. On the other hand, the businesses indi-
cated that the quality of life in Maine has a signifi-
cant positive effect on their ability to grow. The rest
of the business climate factors included in the sur-
vey do not appear to have a significant effect, one
way or another, on the growth of Maine biotechnol-
ogy businesses.
Recommendations
The State of Maine should offer general busi-
ness assistance programs that will benefit a
broad range of biotechnology and other tech-
nology-intensive businesses.
 Steps should be taken to better promote the
programs and resources that are available
to biotechnology businesses in Maine to
create greater awareness of their availabil-
ity.
 The public and private universities in Maine
should undertake a coordinated effort to
publicize the biotechnology-related research
and development activities and collabora-
tions taking place at their respective insti-
tutions.
 The state should continue to support invest-
ments in basic research and development,
including assistance to smaller firms that
present promising development opportuni-
ties but that have few alternative sources of
investment capital
 Further analysis should be conducted on
the costs of doing business in Maine (taxes,
health care, utilities), which biotechnology
businesses report as having a negative ef-
fect on the growth of their operations.
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INTRODUCTION
This report presents the findings from a survey
of biotechnology firms located in Maine. The survey,
conducted during the spring of 2003, collected infor-
mation on a variety of issues related to the compa-
nies operations and the states business climate for
biotechnology. Industry leaders and regional
policymakers may use the survey findings to de-
velop policy recommendations and programs to help
strengthen the industry. The survey and this report
are part of a broader project funded by the Biotech-
nology Association of Maine, the Maine Center for
Innovation in Biotechnology, and the Maine Tech-
nology Institute. Other components of the project
include a report on the economic contribution of the
biotechnology industry to the Maine economy and
the creation of an interactive electronic network
available to biotechnology businesses and other
interested parties.
Economic activity in the United States is in-
creasingly driven by technological innovation and
the development of knowledge-based resources. It is
important, therefore, that economic development
policies and programs at all levels of government
address the needs of technology-intensive indus-
tries. The characteristics of the state and local
business climate that encourage the development of
technology-intensive businesses are often thought
to be different from the locational attributes that
support the growth of traditional, nontechnology-
intensive businesses. Some of the key factors be-
lieved to affect the growth of high-technology firms
are the presence of a skilled workforce, the avail-
ability of investment capital, access to university
and other research facilities, and opportunities for
business-to-business interaction. These issues are
addressed in this report.
INDUSTRY BACKGROUND
Biotechnology is increasingly important in
todays modern economy. According to a recent
industry study, biotechnology-related firms in the
United States, not including the large multina-
tional pharmaceutical companies, employed 150,000
workers and generated $20 billion in sales in 1999
(Ernst & Young 2000). Further, industry output
more than doubled between 1993 and 1999. The
impressive growth of the biotechnology industry
nationally has enticed many states, including Maine,
to pursue biotechnology development as a catalyst
for new business activity and investment. Maines
Science and Technology Action Plan 2001 (Maine
Science and Technology Foundation 2001) and the
State of Maine 2002 Economic Development Strat-
egy (Maine Department of Economic and Commu-
nity Development) both include biotechnology as a
sector targeted for development assistance.
A study of the Maine biotechnology industry
conducted in 2002 uncovered approximately 80
Maine businesses that were conducting research
and development in biotechnology, using biotech-
nology-related processes and products in manufac-
turing and provision of services, and producing
specialized products and services used in biotech-
nology. These firms generated a combined $432
million in annual sales and employed 3,690 work-
ers. Including multiplier effects, the biotechnology
industry contributed $685 million in output to the
Maine economy in 2002 and supported 7,135 Maine
jobs (Allen and Gabe 2002).
SURVEY DATA COLLECTION
Unlike many industries (e.g., automotive, pulp
and paper) that are defined based on an easily
identifiable final product, the biotechnology sector
is defined more on the basis of a companys process
of using living organisms to develop new products or
modify existing ones. For the purposes of this study,
biotechnology is defined as any technique that uses
living organisms or parts of organisms to make or
modify products, to improve plants or animals, or to
develop microorganisms for specific uses (Busch et
al. 1991). The survey population in our study covers
businesses and organizations in Maine that conduct
biotechnology-related research and development,
produce or use biotechnology products and services,
and manufacture specialized equipment and sup-
plies used by biotechnology firms. The terms bio-
technology businesses, companies, and firms
are used interchangeably throughout this report to
include businesses, in addition to research laborato-
ries and institutions.
An anonymous survey of biotechnology compa-
nies operating in Maine was conducted during the
spring of 2003. This survey is contained in appendix
A at the end of the report. The questionnaire was
developed with input and advice from the Biotech-
nology Association of Maine and the survey instru-
ment was pretested by a Maine biotechnology com-
pany. A mailing list of 80 companies was generated
from several electronic and print data sources, in-
cluding general business directories, biotechnology
industry directories, and membership lists from the
Biotechnology Association of Maine. The Biotech-
nology Association of Maine used the mailing list to
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inform businesses of the forthcoming survey and to
solicit their participation.
After the Association received eight returned
mailings due to invalid addresses, an initial mailing
of 72 surveys was sent to Maine biotechnology
companies. A reminder postcard and replacement
survey was sent to nonrespondents, followed by a
telephone solicitation to selected businesses that
did not respond to the mailings. Two of the busi-
nesses that received surveys responded to indicate
that they were not involved in biotechnology-re-
lated activities. We received 40 completed surveys
from the revised sample of 70 firms, which trans-
lates into a response rate of 57%.
Based upon secondary data sources that list
employment figures for nearly all of the biotechnol-
ogy firms in Maine, an analysis of the returned
surveys found that the firms that responded to the
survey were, on average, larger than those that did
not. To account for differences between the sample
of businesses that returned surveys and the overall
industry, the responses were grouped into five em-
ployment size categories and weighted accordingly.
The findings presented in this report are based on
the weighted survey results.
COMPANY DEMOGRAPHIC
CHARACTERISTICS
The biotechnology firms in Maine have been in
operation an average of 14.4 years and have been
located at their present site an average of 9.2 years.
One-fourth of the businesses are less than six years
old, and one-half of the firms are less than ten years
old. Twenty-eight percent of the firms have been in
business for more than 20 years. The survey results
indicate that 80% of the biotechnology businesses in
Maine are privately owned corporations, 10% are
public corporations, and the rest include
proprietorships and nonprofit organizations. Eighty-
one percent of the businesses are single establish-
ment firms, 11% are the headquarters of a multi-
establishment firm, and 8% are a branch plant of a
multi-establishment firm.
Maines biotechnology industry is quite diverse,
both in terms of business size and the scope of
products and services developed and manufactured.
Table 1 shows that industry output and employ-
ment are highly concentrated in a few large firms,
with a relatively small amount of industry activity
contributed by smaller companies. The ten largest
biotechnology employers accounted for an estimated
81% of industry output and 85% of industry employ-
ment in 2002 (Allen and Gabe 2002).
The survey asked each company to indicate its
primary activity from the options of (1) research and
development, (2) making a product, or (3) providing
a service. Since many of the companies are involved
in multiple activities, such as manufacturing firms
that conduct research and development, the per-
centages of firms, by category, sum to more than
100%. Sixty-one percent of the biotechnology com-
panies in Maine manufacture biotechnology-related
products, such as monoclonal antibodies or diagnos-
tic test kits. Forty-six percent of the businesses
listed research and development as one of the
companys primary activities. Finally, 34% of the
businesses are involved in the provision of biotech-
nology services, such as consulting, design and
contract laboratory work.
Companies were also asked to select, from the
options listed in Table 2, the category that best
describes their biotechnology operations. Once again,
the entries in the table sum to more than 100%
because many companies selected multiple catego-
ries. As shown in the far right-hand-side column of
Table 2, Maines biotechnology businesses are some-
what evenly distributed across the major fields of
biotechnology. The largest proportions of firms op-
erate in the areas of human diagnostics (38%),
environmental biotechnology (36%), and marine
biotechnology (31%). The fewest numbers of firms
are engaged in human therapeutics (16%), indus-
trial biotechnology (21%), and genomics or
proteomics (22%).
Figure 1 shows that the industry is highly geo-
graphically concentrated in southern Maine. Ap-
proximately 50% of biotechnology establishments
and 59% of biotechnology jobs are located in
Table 1. Biotechnology activity in Maine, 2002.
Establishment Size Output Employment Establishments
1 to 9 employees  $25,081,672  165  52
10 to 99 employees  $92,415,825  749  23
100 or more employees  $314,780,668  2,775 5
Total  $432,278,165  3,689  80
Source: Allen and Gabe 2002.
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Table 2. Industry categories of Maine biotechnology firms.
Industry Category Biotech R & D Biotech User Industry Supplier Total
-------------------------------------------- % ----------------------------------------
Agricultural biotechnology 26.4 18.1 19.6 26.9
Genomics/proteomics 8.7 13.8 14.3 21.6
Human diagnostics 17.7 17.4 33.0 38.0
Human therapeutics 15.2 0.0 6.0 15.6
Environmental biotechnology 23.9 16.7 24.3 35.8
Industrial biotechnology 11.9 3.2 9.3 21.2
Marine biotechnology 23.9 9.2 18.1 31.3
Animal health 25.6 22.8 17.7 30.2
Biotechnology Establishments
0 - 2 establishments
3 - 5 establishments
6 - 9 establishments
10 or more establishments
95
Figure 1. Locations of Maine biotechnology companies.Source: Allen and Gabe 2002.
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Cumberland and York counties (Allen and Gabe
2002). Many of the companies in southern Maine
owe their existence to two large biotechnology firms
in operation during the 1980s in the greater Port-
land area. When those firms were acquired by out-
of-state corporations and relocated out of Maine,
some former employees chose to remain in the state
and start their own companies (Colgan et al. 2002).
These spin-off companies, started by former
employees of established biotechnology firms, ap-
pear to be a major component of the biotechnology
cluster in southern Maine. According to the survey,
57% of the biotechnology businesses in Cumberland
and York counties were founded by individuals who
previously worked in other Maine biotechnology
firms. By comparison, approximately one-third of
the biotechnology businesses in the mid-Maine re-
gion (Androscoggin, Kennebec, Knox, Lincoln,
Sagadahoc, and Waldo counties) were founded by
former Maine biotechnology employees. None of the
companies located in other parts of the state was
started by former employees of Maine biotechnol-
ogy companies.
BIOTECHNOLOGY INVESTMENT AND
INNOVATION
Table 3 documents the investments in facilities,
machinery and equipment, and research and devel-
opment made by Maine biotechnology companies
during 2002. Forty percent of the businesses ex-
panded their facilities, with nearly one-quarter of
them investing between $50,000 and one-half mil-
lion dollars. By comparison, 88% of the biotechnol-
ogy firms invested money in machinery and equip-
ment, and 92% reported spending money on re-
search and development. The high proportion of
businesses investing in research and development
is not surprising in light of the rapidly emerging
technological advances that characterize the bio-
technology industry. For many companies, gaining
an economic advantage depends upon producing
new innovations, or at least keeping pace with
others in the industry by adopting current and
emergent technologies.
Table 4 shows the sources of funding that sup-
port the research and development expenditures
made by Maines biotechnology companies. The bio-
technology firms in Maine rely heavily on own-
source funding for their investments in research
and development. During 2002, three-fourths of all
biotechnology firms reported using revenue gener-
ated through the sales of products and services to
fund some portion of their research and develop-
ment activities. Across all biotechnology businesses,
own-source revenues provided an average of 63% of
total research and development expenditures. For
the biotechnology companies that used own-source
funding, it provided an average of 84% of their
budget spent on research and development.
The second most common source of research
and development funds is programs administered
by Maine-based agencies or organizations, such as
the Maine Technology Institute and the Finance
Authority of Maine. These agencies provided fund-
ing to 40% of Maine biotechnology companies in
2002 and accounted for an average of 9% of overall
spending on research and development. Other
sources of funds used for research and development
include venture capitalists, and programs spon-
sored by the U.S. government.
Table 5 shows the relative importance, by em-
ployment size category, of own-source funding com-
pared to support received from the Maine Technol-
ogy Institute. Larger businesses are considerably
more likely than smaller Maine biotechnology firms
to use in-house funds for research and development
investment. Only one-fourth of businesses with one
to four employees used own-source funds for re-
search and development investments, while 87% of
Table 3. Investments in Maine biotechnology companies, 2002.
-------------------------------------------- Type of Investment -------------------------------------------------
Amount of Investment Expansion of facilities Machinery and equipment Research and development
----------------------------------------------% -------------------------------------------------------
Zero investment 59.3 12.2 7.5
Less than $50,000 18.0 43.0 29.4
$50,000 to $500,000 22.7 39.6 41.0
More than $500,000 0.0 5.2 22.1
Total 100 100 100
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Table 5. Key sources of R&D funding, by firm size.
--------------- Source of funding for R & D spending ------------------
Business size category Own-source revenues Maine Technology Institute
----------------- Percentage of firms -----------------
1 to 4 employees 25.0 19.5
5 to 9 employees 74.4 4.6
10 to 49 employees 73.2 4.2
50 or more employees 86.7 0.0
Table 4. Sources of R&D funding, 2002.
Percentage of businesses Mean percentage
Funding Source that use funding source of total spending
------------------------ % -----------------------
Own-source revenues (sales) 75.0 63.3
Venture capital 12.9 10.2
State government programs 40.0 9.2
U.S. government programs 14.0 5.1
Other 15.5 1.6
businesses with 50 or more employees reported
using own-source funds for that purpose.
On the other hand, small businesses are more
likely than larger firms to obtain funding from the
Maine Technology Institute. Nearly 20% of busi-
nesses with one to four employees obtained re-
search and development funds from the Maine Tech-
nology Institute, compared to about 4% of the busi-
nesses with five to 49 employees. For those small
businesses that received Maine Technology Insti-
tute funding, it appears to be an important source of
revenue for research and development. The Maine
Technology Institute provided an average of 31% of
the research and development budget for businesses
with one to four employees, compared to 11% of the
research and development budget for businesses
with five to 49 employees.
The success of research and development activi-
ties in the biotechnology industry is often measured
by the number of patents and patents pending held
by businesses. The biotechnology businesses in
Maine hold an average of 2.3 patents and 0.7 pat-
ents pending. These patent numbers are highly
correlated with business size. Firms with fewer
than ten employees average 1.3 and 0.8 patents and
patents pending, respectively. The numbers increase
to 2.2 patents and 2.8 patents pending for business
with between 10 and 50 employees, and to 9.3
patents and 0.5 patents pending for businesses with
more than 50 employees.
Other indicators of innovative activity among
biotechnology companies include the articulation of
plans to increase the level of research and develop-
ment, conduct new product trials, and release new
products. During the next three years, about one-
half of the businesses plan to increase their spend-
ing on research and development, 78% of the Maine
biotechnology firms plan to release a new product,
and 44% plan to enter into new product trials.
COOPERATIVE ACTIVITY
A key factor in the development of technology-
intensive clusters (i.e., geographic concentrations of
economic activity established around a particular
industry or technology) is interaction among firms
and organizations. The sharing of knowledge, ei-
ther directly through formal relationships or indi-
rectly through the movement of workers between
companies, can be beneficial to all parties involved.
Table 6 summarizes the cooperative activities of
Maine biotechnology companies. The far right-hand-
side column is the percentage of companies that
have been involved, at any time, in the selected type
of cooperative activity. Since some businesses have
been involved in multiple partnerships, the sum of
the percentages across each row may exceed the row
total in the far right-hand-side column. The bottom
row shows the percentage of Maine biotechnology
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companies that reported having ever engaged in
cooperative activity with the selected type of part-
ner. Since businesses may have multiple interac-
tions with the same types of partner, the sum of the
percentages down each column may exceed the
column total in the bottom row.
As shown in Table 6, Maine biotechnology firms
are more likely to have relationships with other
businesses than with Maine nonprofit organiza-
tions or university researchers located in Maine.
Fifty percent or more of the businesses reported
partnerships with other Maine companies and busi-
nesses located outside the state, while around one-
third of the businesses have partnered with non-
profit organizations or university researchers lo-
cated in Maine. The most common types of partner-
ships reported are joint research and development
efforts (58%) and the sharing of technical informa-
tion (56%). Of all types of partnerships, businesses
are least likely to coordinate their purchases of
supplies (19%) or participate in a coordinated mar-
keting effort (21%).
As shown in the far left-hand-side column of
Table 6, cooperation between Maine biotechnology
companies most frequently takes the form of shared
technical information (27%), joint research and de-
velopment (22%) and shared facilities, space, equip-
ment and/or personnel (18%). The most common
types of interaction with out-of-state companies are
joint research and development (39%), sharing tech-
nical information (35%), and launching a new prod-
uct (28%). Our survey results show that Maine
businesses are more likely to engage in coordinated
marketing efforts and form strategic alliances with
out-of-state firms than with other businesses lo-
cated in Maine. As might be expected, the biotech-
nology companies located in Maine are more likely
to share equipment and facilities with other Maine
firms than with companies located out of state.
The types of partnerships shown in Table 6 are
closely related to some of the most commonly used
business strategies of biotechnology companies.
These include the formation of joint ventures, par-
ticipation in technology transfers, and the merger
with, or acquisition of, another business. To deter-
mine the direction that Maine biotechnology com-
panies are headed in the near future, the survey
asked respondents to identify the business strate-
gies that they planned to implement during the next
three years. As with the partnerships described in
Table 6, the business strategies shown in Figure 2
are more likely to be directed at businesses or
organizations located outside of the state than at
other Maine entities.
The most common strategy planned by a Maine
biotechnology firm over the next three years is the
creation of a joint venture with another business.
Twenty-two percent of businesses plan to enter into
a joint venture with another Maine business, while
35% plan to pursue a joint venture with a non-
Maine business. The second most common planned
strategy involves obtaining a technology transfer
from a university. Twenty-five percent of businesses
plan to receive technologies from universities lo-
cated outside of Maine, compared to 6% that plan to
obtain technology from a Maine university. Inter-
estingly, a larger percentage of Maine firms are
planning a business acquisition than a merger with
another company. In either case, the acquisition or
merger target is more likely to be an out-of-state
company than another Maine business.
To further gauge the extent to which Maines
biotechnology companies are connected to the re-
gion, as well as to each other, we asked businesses
to indicate what they believed to be important
sources of biotechnology workers. As shown in
Table 7, close to 40% of the businesses viewed other
biotechnology businesses located within the state
Table 6. Partnerships of Maine biotechnology firms.
Other Maine Non-Maine Maine Non-profit Maine University
Cooperative activity Businesses Businesses Organization Researcher Total
------------------------------------------------- %--------------------------------------------------
Conducted joint R&D 22 39 11 20 58
Submitted joint research proposal 14 18 14 10 31
Coordinated marketing effort 6 20 0 0 21
Shared equipment or personnel 18 2 8 14 32
Coordinated purchase of supplies 6 9 5 0 19
Shared technical information 27 35 18 21 56
Formed a strategic alliance 8 21 2 6 28
Shared facilities and space 18 13 9 16 41
Launched a new product 6 28 0 0 26
Total 50 61 32 36
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Table 7. Important sources of biotechnology
workers.
Within Outside
Source Maine of Maine
---------- % ---------
Other biotechnology businesses 39.4 25.7
4-year universities 33.1 30.1
2-year colleges 8.8 2.9
0%
5%
10%
15%
20%
25%
30%
35%
40%
Joint venture Technology transfer Business acquisition Business merger
Pe
rc
en
t
with other Maine entities
with non-Maine entities
Figure 2. Planned strategies of Maine biotechnology firms.
as an important source of new employees. On the
other hand, a quarter of Maine biotechnology busi-
nesses felt that companies located out of state are a
key source of workers. One-third of the businesses
reported that Maines four-year universities are an
important source of employees, compared to 9% of
the companies that felt the states two-year colleges
are an important source of biotechnology workers.
ASSISTANCE RECEIVED BY MAINE
BIOTECHNOLOGY FIRMS
Economic development programs, offered at all
levels of government, are commonly used to encour-
age business growth and development. The U.S.
federal government administers programs that pro-
vide technical assistance in all aspects of business
operations, and financial support in the form of
grants, loans and tax relief. Thirty-four percent of
Maine biotechnology firms applied for federally
funded grants, and 32% successfully received such
funding. Fewer than 10% of businesses received
other types of assistance (e.g., government loans,
contracts, technical assistance) from the U.S. gov-
ernment.
In addition to business-assistance programs
sponsored by the U.S. government, the state of
Maine offers a variety of programs designed to
stimulate business growth (Table 8). Some of these
programs, such as the biotechnology sales tax ex-
emption and programs that support research and
development, appear to be highly relevant to Maine
biotechnology firms. Although some businesses may
not qualify for certain state-sponsored programs, it
is noteworthy that, for six of the eight programs
included in the survey, a larger percentage of busi-
nesses are unaware of the program than the per-
centage that sought assistance. An exception to this
is the grant programs sponsored by the Maine
Technology Institute, which are well known and
well used by Maine biotechnology companies. More
than two-thirds of biotechnology companies either
have applied for, or received, grant funding from the
Maine Technology Institute, and only 8% are un-
aware of the programs.
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Less than 20% of Maine biotechnology busi-
nesses sought or received assistance from any of the
other programs included in the survey, and more
than 20% of the businesses are unaware of sales tax
exemptions available for research and development
or biotechnology-related expenditures. Only 13% of
businesses sought property tax reimbursements on
equipment and machinery through the BETR pro-
gram, and 17% are unaware of the programs exist-
ence. This is surprising given the significant public-
ity that has surrounded the program in recent years
and its availability to all businesses, regardless of
size or industry.
The respondents were also asked to indicate if,
beyond the provision of financial assistance, se-
lected organizations in Maine played a role in the
establishment of partnerships, new product devel-
opment, or establishment of new markets. Of these
three types of assistance, businesses were most
likely to receive assistance, from the sources listed
in Table 9, with new product development (41%),
followed by the establishment of partnerships (24%),
and new markets (15%).
As shown in Table 9, the organization that most
often provides these types of assistance to Maine
biotechnology companies is the Maine Technology
Institute (MTI). Thirty-nine percent of the busi-
nesses received assistance from the MTI in the area
of new product development, while 20% indicated
that the MTI was instrumental in the establish-
ment of a partnership. The Maine International
Trade Center provided assistance to Maine biotech-
nology businesses in the areas of establishing part-
nerships (12%) and establishing new markets (3%).
The University of Maine System assisted biotech-
nology businesses primarily in the areas of new
product development (8%) and the establishment of
partnerships (5%). No other organization provided
these types of assistance to more than 10% of the
businesses surveyed.
BUSINESS CLIMATE
A regions business climate refers to the array of
attributes associated with a given location that
affect businesses, or that business people perceive
as having some impact upon their operations. These
locational characteristics typically include govern-
ment policy as it relates to regulatory matters, but
can also take account of the availability of financ-
ing, education and workforce concerns, and life-
style issues.
Maine biotechnology companies were asked to
respond to a number of business climate factors and
to indicate whether or not the factor is relevant to
the growth or profitability of the business. For each
relevant factor, respondents were asked to rate its
effect in Maine using a numerical scale ranging
Table 8. State government programs for biotechnology.
State Government Programs Sought or received assistance Unaware of the program
------------------------ % ----------------------
Maine Technology Institute grant 69 8
Employee training programs 18 6
Biotechnology sales tax exemption 12 21
Research expense credit 9 16
Super R&D credit 5 19
Tax increment-financing (TIF) incentive 4 6
Business Equipment Property Tax Reimbursement (BETR) 13 17
Research & development sales tax exemption 15 23
Table 9. Entities that support Maine biotechnology firms.
Source of assistance Percentage receiving assistance
Maine Technology Institute 42.0
Maine International Trade Center 13.7
University of Maine System 12.4
Maine Dept. of Economic & Community Development 6.9
Maine Science and Technology Foundation 5.3
Maine Technical College System 2.7
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Negative growth factors:
State sales and income taxes
Municipal property taxes
Workers Compensation costs
Healthcare costs
Utility costs
Neutral growth factors:
Access to in-state venture capital
Access to in-state debt financing
Availability of state funding for R&D
Distribution and transportation costs
Labor costs
State govt. business regulations
Local zoning and permitting regs.
State environmental regulations
Location relative to key markets
Location relative to suppliers
Availability of qualified employees
Access to university research info.
Availability of specialized equipment
Interaction with other biotech firms
Availability of business services
Quality of local schools
Local infrastructure and services
State and local tax incentives
Views of Maine policy makers
Support of local policy makers
Public perception of biotechnology
Strength of industry association
Positive growth factor:
Maines quality of life
statistically significant positive (negative) impact
on growth. We conducted statistical analyses of the
business-climate ratings to determine the factor
averages that are significantly greater, or less, than
a neutral rating of 4.0. The factors that have an
average rating that is significantly less than 4.0, at
a 10% significance level, are shown in Figure 3 as
negative growth factors. The factor that has an
average rating that is significantly greater than 4.0,
at a 10% significance level, is shown as a positive
growth factor.
As shown in Table 10, the business-climate
factors addressed in the survey generally are re-
ported to be relevant to the biotechnology industry.
Only two business-climate factors, access to in-state
venture capital and access to in-state financing,
reportedly affect business growth for less than one-
half of Maine biotechnology companies. The busi-
ness-climate factors that affect the largest percent-
ages of companies are workers compensation costs,
health care costs, and utility costs. These were
reported to affect 92%, 92%, and 89% of biotechnol-
ogy businesses, respectively. The biotechnology com-
panies indicated that these business costs are nega-
tive growth factors.
Financing Issues
Less than 40% of the businesses reported that
access to in-state venture capital or debt financing
have an impact on the growth potential of their
business. Access to venture capital received an
average rating of 3.2, while the availability of in-
state debt financing received a rating of 4.7. State-
sponsored programs, such as those offered by the
Maine Technology Institute, affect 64% of biotech-
nology businesses. These programs received a mean
rating of 4.8. None of the financing issues included
in the survey received an average score that is
significantly different from a neutral rating of 4.0.
Business Costs and Regulations
The survey asked businesses to rate ten busi-
ness climate factors that reflect the costs of doing
business in the region. Some of these factors, such
as workers compensation and health care costs, are
considered to be relevant issues by more than 90%
of biotechnology businesses. Other business costs
and regulations, such as distribution and transpor-
tation costs, local zoning and permitting, and state
environmental regulations, affect fewer than 65%
of biotechnology businesses. The cost of labor is the
only factor in this category to receive a rating
greater than 4.0, but the average score of 4.1 is not
significantly greater than a neutral rating of 4.0.
Figure 3. Maines business climate for
biotechnology.
from 1 (very negative) to 7 (very positive). A
neutral effect is assigned a value of 4.
Table 10 summarizes the survey results related
to the states business climate for biotechnology.
The table shows the percentage of businesses that
felt a particular factor affected its growth and the
average rating assigned by businesses that indi-
cated the factor is a relevant issue.
For some of the factors shown in Table 10, the
average rating may be an imprecise indicator of the
factors impact on growth. This is because, in some
cases, the growth factors rating has a wide varia-
tion around its mean score. For example, a growth
factor that has an average rating that is slightly
greater (less) than 4.0, but that has a sufficiently
large variation around the mean, may not have a
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Table 10. Average ratings of business-climate factors.
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Health care costs, a factor with the most wide-
spread impact, received the lowest score (mean
score of 1.5) of all business-climate factors. Other
factors in this section that received among the
lowest business-climate ratings are state sales and
income taxes (mean score of 2.1), workers compen-
sation costs (mean score of 2.2), municipal property
taxes (mean score of 2.3), and utility costs (mean
score of 2.6). Each of these factors received an
average score that is significantly less than a neu-
tral rating of 4.0. This implies that these business
cost factors are perceived to have a negative effect
on the growth of Maine biotechnology businesses.
Local Issues
This category includes business-climate factors
that may pertain to the town or city where the
business is located. These factors capture general
characteristics of the local area, such as the quality
of local schools and infrastructure, as well as the
benefits that businesses are believed to receive from
operating within an industry cluster. These ben-
efits, which are external to the business but internal
to the cluster, may include the presence of a skilled
workforce, the availability of specialized machin-
ery, and the ability to interact with other biotech-
nology businesses. None of the factors in this cat-
egory received an average score that is significantly
different from a neutral rating of 4.0.
Three of the location factors in this category are
relevant to a relatively large percentage of the
biotechnology companies. The availability of quali-
fied biotechnology employees and access to univer-
sity based research information affect 81% and 82%
of the businesses, respectively. Seventy-eight per-
cent indicated that business growth is affected by
their ability to interact with other biotechnology
companies.
Other Business-Climate Factors
This category includes six additional business-
climate factors. Three of these reflect the level of
support for biotechnology from outside of the indus-
try, as perceived by companies within the industry.
The views of Maine state government policymakers,
support of local policymakers, and the publics per-
ception of the biotechnology industry all appear to
be relevant issues to Maines biotechnology busi-
nesses. As might be expected, the views of state
government policymakers are reported to affect a
substantial percentage of biotechnology businesses
(84%), followed by the views of local policymakers
(77%), and the publics perception of the industry
(66%). None of these business climate factors re-
ceived an average score that is significantly differ-
ent from a neutral rating of 4.0.
Sixty-one percent of the companies indicated
that the strength of the biotechnology industry
association affects the growth of their business. The
industry association(s) received an average score of
3.7, which is not significantly different from a neu-
tral rating of 4.0. Finally, the quality of life offered
by a Maine location is perceived to affect the growth
of 85% of the biotechnology businesses. With an
average rating of 5.8, Maines quality of life is the
highest ranked growth factor and the only factor
covered in the survey that received an average score
that is significantly greater than a neutral rating of
4.0. The states quality of life appears to be a positive
force in the industrys business climate.
RESPONSES TO OPEN-ENDED
QUESTIONS
The survey included several open-ended ques-
tions that asked biotechnology companies to com-
ment on the strengths and weaknesses of operating
in Maine and the changes they believe would help
their competitiveness. The responses to these ques-
tions generally reinforced the trends revealed else-
where in the survey. When asked to indicate what
actions, policy changes, or assistance the state of
Maine could provide to enhance the competitive-
ness of biotechnology firms, the most frequent re-
sponse (43% of firms) involved lowering the costs of
doing business. This notion is further supported by
the responses provided to another open-ended ques-
tion that asked the firms to indicate the three
primary drawbacks of operating a biotechnology
business in Maine. Of the 38 firms that provided a
response, two-thirds remarked on the high costs of
doing business in Maine. Although high taxes were
the most frequent target, other cited costs included
the expense of providing health care coverage for
employees and the cost of workers compensation.
The second most frequent suggestion (25% of
respondents) for improving the competitiveness of
biotechnology businesses centered on the issue of
financing. Some firms pointed to the need to attract
more federal research and development dollars,
while others felt that some state government fund-
ing programs were not accessible to all businesses.
Nearly as many respondents (21% of the businesses)
indicated that improved access to technical resources
could help improve the industrys competitiveness.
This is reinforced by the relatively large group (29%
of respondents) that reported a lack of research and
development resources in the state as one of the
primary drawbacks to doing business in Maine.
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Specifically, 20% of the respondents mentioned sev-
eral issues of concern related to the University of
Maine system, including the location, amount, and
accessibility of university resources.
The second most often-cited drawback to oper-
ating a biotechnology business in Maine, behind the
costs of doing business, is the states remote location
relative to national centers of biotechnology activ-
ity. This concern, cited by 60% of the respondents,
generally revolved around a firms perceived isola-
tion from developments in the industry and the
difficulty of recruiting scientists from outside of
Maine. Despite these feelings of isolation, about
60% of the businesses believed they would not ben-
efit from greater interaction with other biotechnol-
ogy businesses. The most common explanation for
this response is that Maine biotechnology busi-
nesses are too specialized to benefit from (general)
collaborations that are not specific to their companys
activities.
In response to the question of why their busi-
ness is located in Maine and why they stay here, the
largest numbers of respondents mentioned Maines
quality of life (55%), or indicated that the firms
founder was already living in Maine when the com-
pany was established (55%). Other firms (26%),
especially those involved in aquaculture, referred to
the presence of the states natural resources as a
primary reason for locating in Maine. Finally, some
businesses (17%) indicated that the states labor
force is a primary benefit of operating in Maine.
Most comments in this regard, however, referred to
the strong work ethic and dependability of Maine
workers, while no one positively remarked about
the educational background of the states workforce.
On the contrary, almost 20% of the respondents
cited the limited availability of qualified employees
as a drawback to operating in Maine.
SUMMARY AND CONCLUSIONS
The Maine biotechnology industry is made up of
about 80 businesses. These companies are engaged
in research and development in addition to the
manufacturing and provision of a wide variety of
products and services. Although the industry is
defined based upon the use and support of a com-
mon general technology, businesses that constitute
the industry appear to be quite diverse in terms of
the specific focus area of biotechnology. The busi-
nesses cover a broad spectrum of the biotechnology
industry, from human diagnostics to marine bio-
technology to genomics and proteomics. This diver-
sity likely explains some of the survey findings
related to the limited benefits from industry clus-
tering. Further, the lack of a critical mass in any one
type of biotechnology likely explains why some Maine
biotechnology companies are just as likely, or even
more likely, to partner with companies and univer-
sities located outside of Maine than to cooperate
with other in-state entities.
The survey results suggest that Maine biotech-
nology companies are actively involved in research
and development, which is key to success in technol-
ogy-intensive industries. Large companies gener-
ally finance the bulk of their research and develop-
ment expenditures through their own revenue
sources, while small businesses are likely to receive
support for research and development from state-
sponsored programs such as those administered by
the Maine Technology Institute. The research and
development activities in Maine biotechnology com-
panies appear to be leading to new products, as 78%
of the businesses are planning to release a new
product in the next three years. Further, Maine
biotechnology companies hold an average of 2.3
patents and 0.7 patents pending.
The evidence is mixed on the question of whether
the biotechnology industry in Maine generates sub-
stantial cluster benefits. On the one hand, the in-
dustry is highly concentrated in southern Maine
and a large number of biotechnology businesses in
that area are the result of spin-off ventures started
by former employees of other biotechnology busi-
nesses. On the other hand, industry cluster benefits
related to the presence of a skilled workforce, the
availability of specialized machinery, and intra-
business knowledge spillovers appear to be limited
in Maine. Further, Maine biotechnology businesses
are more likely to seek cooperative links with firms
and universities located outside of the state than
with other Maine-based entities. Firms appear to be
collaborating with entities from outside of the state
because suitable partners are not located within the
state. This is, again, likely a result of the high
diversity within the Maine biotechnology industry.
Biotechnology companies generally believe that
many of the costs of doing business in the state are
harmful to their growth. The majority of survey
respondents feel that the costs of health care, work-
ers compensation, utilities, and state and local taxes
are relevant to the growth of their business. Fur-
ther, statistical analysis of the survey results sug-
gests that these cost factors are perceived to have a
significant negative effect on a biotechnology
companys ability to grow in Maine. On the other
hand, the businesses indicated that the quality of
life in Maine has a significant positive effect on their
ability to grow. The rest of the business climate
factors included in the survey do not appear to have
Maine Agricultural and Forest Experiment Station Miscellaneous Report 43214
a significant effect, one way or the other, on the
growth of Maine biotechnology businesses.
Based on the survey results and analysis pre-
sented in this report, we offer the following recom-
mendations to support the biotechnology industry
in Maine. First, the state should recognize the
industrys diversity when designing biotechnology-
related programs and services. Programs targeted
at specific types of biotechnology will affect only a
small number of firms, while a larger percentage of
the overall industry could potentially benefit from
general services and programs. Moreover, there is
no clear evidence that a cluster has yet emerged
around a specific type of biotechnology that could be
the target for specialized assistance. At this stage of
the industrys development, it is important that
programs make their assistance available to firms
across the industry regardless of specific technology
or firm size. Concentrating on a more general ap-
proach would benefit all types of biotechnology
firms, as well as businesses in other technology-
intensive industries.
Second, the state should widely promote the
economic development programs available to bio-
technology companies. As discussed earlier in the
report, a relatively small percentage of businesses
have used programs other than those offered by the
Maine Technology Institute. In many cases, the
percentage of businesses that have used a program
is actually smaller than the percentage that is
unaware of the programs existence. Similarly, busi-
nesses in the industry reported only limited interac-
tion with university researchers located within the
state. The level of industry diversity and variety of
research projects at Maine colleges and universities
suggests that improved coordination and communi-
cation could increase the potential for industry-
university partnerships. The programs available to
biotechnology companies could be promoted through
the administering agencies, the states industry
association, and the newly formed biotechnology
interactive network.
Third, the state should continue to support
investments in basic research and development.
Nearly two-thirds of the survey respondents believe
that the availability of state government funding
for research and development is relevant to the
growth of their business. Further, the state-spon-
sored research and development programs appear
to be especially important to small biotechnology
companies, which are less likely than larger firms to
finance research and development through rev-
enues generated by the business. Once again, pro-
grams that support basic research in all types of
biotechnology would benefit a larger number of
firms than programs targeted at specific types of
research and development.
Fourth, further analysis should be conducted on
the costs of doing business in Maine, including the
costs of health care, workers compensation, utili-
ties, and taxes. The biotechnology companies were
in almost unanimous agreement that these costs
are relevant to their operations, and the businesses
generally felt that these location factors in Maine
have a negative effect on their ability to grow.
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Survey Information and Instructions
Please complete and return this voluntary survey if your establishment performs biotechnology research
and development, manufactures biotechnology-related products, uses biotechnology in manufacturing
or provision of services, or provides goods and services that are used by biotechnology companies.
Our goal is to treat your responses with the utmost confidentiality.  Do not write your name or the name
of your establishment on the survey.  Your establishment name is written on the postcard.  The returned
postcards will provide us with an accurate account of which companies participated in the study.
Your responses to the survey are strictly confidential and will never be associated with your name or the
name of your business.  Study results will be presented only in aggregate for the entire industry or for
subsets of the industry that contain three or more businesses.  Individual surveys will be processed by
a single researcher at the University of Maine.  The completed surveys will be stored in a locked file
cabinet and will be shredded upon completion of the study.
Please make sure that all of your responses are complete.  You may, however, skip over any
question that you feel uncomfortable answering.  Also, you may write additional comments in the
margin of the survey.
If information required to answer a question is not readily available, please provide the most accurate
estimate possible.  If an item does not apply to your firm, please designate with the letters N/A.
The survey should take approximately 20 minutes to complete.  Except for your time and inconvenience,
there are no risks to participating in the study.
Questions related to this survey should be directed to:
Todd Gabe, Assistant Professor, (207) 581-3307
Thomas Allen, Associate Scientist, (207) 581-3164
Questions related to your rights as a study participant should be directed to:
Gayle Anderson, Special Assistant for Research Administration, (207) 581-1498
Please return the completed survey, in the enclosed pre-addressed envelope, to the address shown below.
Returning the survey implies consent to participate.
Biotechnology Survey
Department of Resource Economics and Policy
University of Maine
5782 Winslow Hall
Orono, ME  04469-5782
Thank you for your participation.
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1) In what year was your organization or business established in Maine? ________________
2) How many years has your establishment been operating at its current location? _________
3) From the following list, please check the option(s) that best describe(s) the ownership
structure of your establishment:
____ proprietorship or partnership (any form)
____ privately-owned corporation
____ publicly-owned corporation
____ non-profit organization
____ other (please indicate: ________________________________________________ )
4) From the following list, please check the option(s) that best describe(s) the organizational
structure of your establishment:
____ single establishment firm
____ headquarters of multi-establishment firm
____ branch plant of multi-establishment firm
____ establishment of a multi-national corporation
____ other (please indicate: ________________________________________________ )
5) From the following list, please check the option(s) that best describe(s) the primary activity
of your establishment:
____ research and development
____ making a product(s)
____ providing a service
____ other (please indicate: ________________________________________________ )
6) Where is your establishment located?
___________________ Zip Code ___________________ County
7) Was the founder of this business previously employed by another biotechnology-related
business in Maine?
Yes   No
Maine Agricultural and Forest Experiment Station Miscellaneous Report 43218
8) For each category of biotechnology that applies to your establishment, please indicate if your
establishment a) conducts research and development in biotechnology, b) uses
biotechnology or biotechnology products in manufacturing or provision of services, or c)
supplies other products or services used by biotechnology companies (check all that apply).
Biotech Uses Industry
Category R & D Biotech Supplier
Agricultural biotechnology  (e.g., biopesticides, diagnostics, genetically
modified foods, natural fertilizers, nutraceuticals)
Genomics / proteomics  (e.g., bioinformatics, DNA diagnostics,
pharmacogenetics)
Human diagnostics  (e.g., biological sensors, gene tagging, monoclonal
antibodies, polymerase chain reaction amplification)
Human therapeutics  (e.g., biopharmaceuticals, gene therapy, human
growth hormones, vaccines)
Environmental biotechnology  (e.g., biofiltration, bioremediation,
environmental monitoring, immunoassays, microbial mining,
phytoremediation)
Industrial biotechnology  (e.g., specialty amino acids and enzymes,
bioprocessing, phytochemicals, other industrial activities)
Marine biotechnology  (e.g., aquaculture, new classes of human health
and medical products, and other chemical products)
Animal health  (e.g., animal diagnostics and therapeutics, monoclonal
antibodies, transgenic animals)
Other (please indicate:___________________________________________________________________
_____________________________________________________________________________________
9) How many workers in total did your establishment employ as of January 1, 2003?
__________ Full-time employees
__________ Part-time employees
10) How many of these workers have biotechnology-related responsibilities?
__________ Full-time employees
__________ Part-time employees
11) Does your firm currently have any full-time biotechnology-related positions that have been
unfilled for more than three months? Yes No
If yes, please describe the position(s): ______________________________________________________
__________________________________________________________________________________________
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12) What is the approximate number of full-time workers with biotechnology-related
responsibilities in each of the following occupations?
Number of
Occupation Employees
Scientists
Engineers
Laboratory Technicians
Computer Programmers and Information Technology
Managers and Supervisors
13) What is the approximate number of full-time workers with biotechnology-related
responsibilities that have obtained the following (highest) levels of education?
Number of
Level of Education Employees
High school diploma or general education degree
Graduate of 2-year community college, or technical school
Graduate of 4-year university (B.S. or B.A. degree)
Masters degree
Doctorate degree
14) Indicate which of the following have been important sources of biotechnology workers for
your establishment (check all that apply).
Important Source of
Background Biotechnology Workers
Another establishment located in Maine
Another establishment located elsewhere in the U.S.
4-year university located in Maine
4-year university located elsewhere in the U.S.
2-year university located in Maine
2-year university located elsewhere in the U.S.
Establishment or university located outside the U.S.
Other (please specify):______________________________
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15) What was your establishments total sales revenue in 2002?
Zero Zero to $250K  $250K to $500K
$500K to $750K $750K to $1 million  $1 million to $2.5 million
$2.5 million to $5 million  $5 million to $10 million  More than $10 million
16) How much did your establishment receive in total grants in 2002?
Zero Zero to $250K  $250K to $500K
$500K to $750K $750K to $1 million  $1 million to $2.5 million
$2.5 million to $5 million  $5 million to $10 million  More than $10 million
17) How much did your establishment receive in total contracts or fees in 2002?
Zero Zero to $250K  $250K to $500K
$500K to $750K $750K to $1 million  $1 million to $2.5 million
$2.5 million to $5 million  $5 million to $10 million  More than $10 million
18) How much did your establishment spend on facility expansions in 2002?
Zero Zero to $250K  $250K to $500K
$500K to $750K $750K to $1 million  $1 million to $2.5 million
$2.5 million to $5 million  $5 million to $10 million  More than $10 million
19) How much did your establishment spend on new equipment and machinery in 2002?
Zero Zero to $250K  $250K to $500K
$500K to $750K $750K to $1 million  $1 million to $2.5 million
$2.5 million to $5 million  $5 million to $10 million  More than $10 million
20) How much did your establishment spend on payroll (including benefits) in 2002?
Zero Zero to $250K  $250K to $500K
$500K to $750K $750K to $1 million  $1 million to $2.5 million
$2.5 million to $5 million  $5 million to $10 million  More than $10 million
21) How much did your establishment spend on research and development in 2002?
Zero Zero to $250K  $250K to $500K
$500K to $750K $750K to $1 million  $1 million to $2.5 million
$2.5 million to $5 million  $5 million to $10 million  More than $10 million
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22) What percentage of your establishments research and development budget in 2002 came
from the following sources?
Percentage of
Revenue Source R&D Budget
Revenue generated by product sales %
Conventional loans %
In-state venture capital %
Out-of-state venture capital %
Grants or loans from the U.S. government %
Grants or loans from the Finance Authority of Maine (FAME) %
Grants or loans from the Maine Technology Institute (MTI) %
Grants of loans from another Maine agency/program: _____________ %
Grants from a private research foundation %
Other (please indicate:___________________________) %
    Total 100 %
23) How many patents or patents pending does your establishment have?
________ patents ________ patents pending
24) What percentage of your establishments total sales in 2002 was generated from foreign
exports of biotechnology products or processes?
Zero Zero to 10 percent 10 percent to 25 percent
25 percent to 50 percent 50 percent to 75 percent 75 percent  to 100 percent
25) Please list the four countries that received the highest percentage of your establishments
exports in 2002.
1._________________________________________________________
2._________________________________________________________
3._________________________________________________________
4._________________________________________________________
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26) What percentage of your purchased inputs, materials or equipment is obtained through
foreign imports?
Zero Zero to 10 percent 10 percent to 25 percent
25 percent to 50 percent 50 percent to 75 percent 75 percent  to 100 percent
27) Please list the four countries from which your establishment purchased the highest
percentage of imported goods in 2002.
1._________________________________________________________
2._________________________________________________________
3._________________________________________________________
4._________________________________________________________
28) Please check the following business strategies that your business has used in the last 12
months, or is planning to use in the next 12 months, or next 3 years (check all that apply).
Last 12 Next 12 Next 3
Strategy months months years
Release a new product
Enter product trials
Substantial increase in research and development activities
Form a joint venture with another Maine establishment
Form a joint venture with establishment outside of Maine
Technology transfer from a university located in Maine
Technology transfer from a university located out of Maine
Acquire another establishment located in Maine
Acquire another establishment located outside of Maine
Merge with another establishment located in Maine
Merge with another establishment located outside of Maine
Relocate outside of Maine
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29) Check the expansion activities that your establishment has completed in the last 12 months,
or is planning to complete in the next 12 months, or next 3 years (check all that apply).
Last 12 Next 12 Next 3
Expansion Activity months months years
Expand facilities by less than 2,500 square feet
Expand facilities by 2,500 to 10,000 square feet
Expand facilities by more than 10,000 square feet
New equipment purchases of less than $1 million
New equipment purchases of $1 million to $10 million
New equipment purchases of more than $10 million
30) Please indicate whether your establishment has been involved in any of the following types
of interaction with the federal government during the past three years (check all that apply).
U.S. Government Interaction Past 3 years
Received technical assistance from the U.S. government
Applied for grants from the U.S. government
Received government grants from the U.S. government
Obtained federal government loans
Awarded a federal government contract
Other (please indicate):______________________________
31) Please indicate if, during the past three years, your establishment sought or received
assistance from the following Maine state government programs (check all the apply).
Sought Received Unaware of
State Government Programs Assistance Assistance the Program
Maine Technology Institute (MTI) grant
Employee training programs
Biotechnology sales tax exemption
Research expense credit
Super R&D credit
Tax increment-financing (TIF) incentive
Bus. Equip. Property Tax Reimbursement (BETR)
Research & development sales tax exemption
Other (please indicate): ____________________
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32) Please indicate if your business has ever engaged in the following types of cooperation with other
biotechnology businesses in Maine, other biotechnology businesses located outside of Maine, non-
profit organizations in Maine, or University of Maine researchers (check all that apply).
Maine Maine
Other Maine Non-Maine Non-profit University
Cooperative activity Businesses Businesses organization Researcher
Conducted joint R&D
Submitted a joint research proposal
Coordinated marketing effort
Shared equipment or personnel
Coordinated purchase of supplies
Shared technical information
Formed a strategic alliance
Shared facilities and space
Launched a new product
33) Please indicate whether each of the following Maine state-sponsored agencies, programs or
institutions have ever contributed to the establishment of partnerships, new product
development, or new markets for your business (check all that apply).
Establishment of New Product Establishment of
Cooperative activity Partnerships Development New Markets
University of Maine System
Maine Technical College System
Maine Science & Technology Foundation
Maine Technology Institute
Dept. of Economic & Community Development
Maine International Trade Center
Other: _________________________
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34) Please rate the degree to which the following factors in Maine affect your establishments
profitability or growth potential, with 1 being a strongly negative factor and 7 being a
strongly positive factor.  If it does not affect your businesss growth, select Not a factor.
Not a Negative Positive
Factor 1 2 3 4 5 6 7
FINANCING
Access to in-state venture capital
Access to in-state debt financing
Availability of state government funding for R&D
BUSINESS COSTS AND REGULATIONS
Distribution and transportation costs
Labor Costs
State sales and income taxes
Municipal personal property tax
Workers Compensation costs
Health care costs
Utility costs
State government business regulations
Local zoning and permitting practices
State environmental regulations
LOCATION ISSUES
Location relative to key output markets
Location relative to key materials & supplies
Availability of qualified biotechnology employees
Access to university-based research information
Availability of specialized equipment
Interaction with other biotechnology businesses
Availability of business services (legal, accounting, etc.)
Quality of local schools (K-12)
Local infrastructure and public services
OTHER
State and local tax incentives
Views of Maine government policymakers
Support of local (i.e., municipal/regional) policymakers
Public perception of biotechnology industry
Strength of state industry association(s)
Maines quality of life
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35) If your establishment has not collaborated with other businesses or organizations in the past,
do you feel that it could benefit from greater interaction with other biotechnology firms in
the future?
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
36) What additional actions, policy changes, regulatory reforms, or assistance could the State
of Maine take or provide to help your establishment improve its competitiveness?
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
37) What are the three primary factors that led you to locate and/or maintain your business in
Maine?
1) _______________________________________________________________________
2) _______________________________________________________________________
3) _______________________________________________________________________
38) What are the three primary drawbacks of operating your business in Maine?
1) _______________________________________________________________________
2) _______________________________________________________________________
3) _______________________________________________________________________
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